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In the fatal neuromuscular disease,
Duchenne muscular dystrophy (DMD),
exhaustion of the muscle stem (satellite)
cell pool drives muscle wasting through
mismatched degeneration and regeneration
processes (Forcina et al. 2019). For this
reason, the development of regenerative
myoblast transfer therapeutics has been
pursued for more than two decades, but to
no avail. Skeletal muscle is a dynamically
plastic organ capable of responding and
adapting to mechanical and biochemical
injury so as to match the physicality
and functionality of muscles to the
external demands placed upon them. In
this way, humans can grow bigger and
stronger muscles or, conversely, leaner
yet more functionally durable muscles
to promote organismal survival according
to environmental cues. As such, skeletal
muscle is in a constant state of ‘turnover’
facilitated by satellite cell proliferation,
differentiation and self-renewal (Forcina
et al. 2019). These processes are highly
amenable to amplification by a variety
of factors when more muscle tissue is
required, i.e. during growth or muscle
degeneration/injury. Chronic pathologies
such as DMD present a unique inter-
nal landscape which challenges muscle
plasticity (Dumont & Rudnicki, 2016) and,
consequently, human survival.
Satellite stem cells reside in a niche between
the sarcolemma and basal lamina (Forcina
et al. 2019). They are particularly responsive
to inflammatory and muscle-specific cyto-
kines, which are released during stress,
damage and inflammation (Forcina et al.
2019). Their activity is also highly regulated
by growth factors, local and distant
non-muscle cells (such as fibro-adipocytes,
immune cells etc.), proteins associated with
the dystrophin-associated glycoprotein
complex (DGC), micro and long
non-encoding RNAs, and telomeric
activity (Forcina et al. 2019). When
quiescent satellite cells are activated to
re-enter the cell cycle, two daughter cells are
produced which have one of two potential
fates. Asymmetric division produces one
committed muscle progenitor and one
stem cell to facilitate both muscle repair
and self-renewal of the satellite pool
(Dumont & Rudnicki, 2016). In contrast,
symmetric division enables rapid expansion
of the satellite cell pool by producing two
stem cells (Dumont & Rudnicki, 2016).
A balance between asymmetric and
symmetric division is crucial for enabling
rapid muscle repair during acute injury,
as well as for maintaining the long-term
regenerative potential of skeletal muscle.
Just as important is the capacity of satellite
cells to flux between activation/proliferation
and periods of quiescence (Dumont &
Rudnicki, 2016). This is because with each
cell cycle, telomeric DNA is shortened and
the capacity for satellite cell proliferation
is proportionately diminished unto
exhaustion (Forcina et al. 2019). Dystrophic
satellite cells, which carry loss-of-function
mutation(s) in the dystrophin gene,
manifest stark differences in function
compared to healthy satellite cells (Dumont
& Rudnicki, 2016). Dystrophin protein,
as well as other DGC proteins, is integral
for maintaining asymmetric satellite cell
division and without it, muscle regenerative
capacity is compromised (Dumont &
Rudnicki, 2016).
Micro-RNAs (miR) are short,
non-encoding RNAs that have emerged as
important post-transcriptional regulators
of many genes including those that control
satellite cell activity, muscle growth and
regeneration (Forcina et al. 2019). In this
issue of The Journal of Physiology, Taetzsch
et al. (2021) describe for the first time
the temporal changes in muscle-specific
miR-133b throughout the pathogenesis
of murine (mdx) DMD and the effect of
miR-133b deletion on the mdx phenotype.
Although it is the ‘gold-standard’ animal
model of DMD because of its genetic
homology to human DMD, the mdx
mouse has a peculiar phenotype making
translational research challenging. Many
studies fail to recognise that mdx mice
enter a stabilised ‘remission’ phase from
5 postnatal weeks of age, following an
intense muscle damage, inflammation and
regeneration phase lasting from 3 to
5 postnatal weeks of age. Taetzsch et al.
address this aspect by investigating multiple
time points and importantly show that
miRNA-133b is robustly expressed in mdx
muscles, and significantly more so in the
severe compared to the remission phase of
mdx MD (Taetzsch et al. 2021). Genetic
knockout of miR-133b had little effect on
wild-type muscles, yet it exacerbated MD
in mdx mice, suggesting that miR-133b
attenuates the severity of DMD-associated
myopathy (Taetzsch et al. 2021). Taetzsch
et al.’s data highlight that miR-133b
is crucial for mediating the molecular
response to damage which facilitates repair
and regeneration of skeletal muscle and
could thus be targeted through genetic
or pharmacological intervention as a
treatment for DMD.
While the mechanisms governing
miR-133b’s influence on DMD were not
extensively investigated, an interesting
revelation was that pathways involving
STAT3 and TGF-β/Smad were upregulated
while pathways governing fat metabolism
were downregulated in mdx/miR-133b−/−
muscles (Taetzsch et al. 2021). Paradoxically,
STAT3 signalling is associated with both
hypertrophy and atrophy of muscles
through controlling satellite cell fate –
presumably by manipulating the balance
between proliferation and differentiation
(Guadagnin et al. 2018). When STAT3
inhibitors are administered to mdx mice,
muscle repair and regeneration is sustained
through expansion of the satellite cell
pool but when STAT3 is depleted, the
satellite pool gradually diminishes and MD
is exacerbated (reviewed in Guadagnin
et al. 2018). miR-133b appears to be a
strong regulator of STAT signalling to
enhance muscle regeneration, and/or
of other similarly functioning satellite
regulators such as myostatin. Myostatin is
a growth factor of the TGF-β superfamily
C© 2020 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society DOI: 10.1113/JP280872
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution
and reproduction in any medium, provided the original work is properly cited.
6 Perspectives J Physiol 599.1
and induces Smad-dependent repression
of postnatal muscle growth (Guadagnin
et al. 2018). However, very different
roles are purported for myostatin during
embryonic myogenesis, where it controls
satellite cell fate in a similar fashion to
STAT3 (Guadagnin et al. 2018). Other
miRNAs have established regulatory
function over myostatin and so too might
miR-133b, either directly or through inter-
play with other miRs. Altering metabolic
substrate utilisation could be another
therapeutic mechanism of miR-133b,
since dystrophin-deficient muscles have
well-documented mitochondrial and
other metabolic deficits, which, when
therapeutically targeted, can attenuate
MD (Timpani et al. 2020). Although the
precise mechanisms require unravelling,
Taetzsch et al. highlight miR-133b as a
potential ‘micro’ therapeutic target against
the severity and progression of DMD.
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